Abstract:Background The liver is the third most common metastatic site for advanced breast cancer (BC), and liver metastases predict poor prognoses. However, the characteristic biomarkers of BC liver metastases and the biological role of secreted protein acidic and rich in cysteine-like 1 ( SPARCL1 ) in BC remain unclear. The present study aimed to identify potential biomarkers for liver metastasis of BC and to investigate the effect of SPARCL1 on BC. Methods The publicly available GSE124648 dataset was used to identify differentially expressed genes (DEGs) between BC and liver metastases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to annotate these DEGs and understand the biological functions in which they are involved. A protein–protein interaction (PPI) network was constructed to identify metastasis-related hub genes and further validated in a second independent dataset ( GSE58708 ). Clinicopathological correlation of hub gene expression in patients with BC was determined. Gene set enrichment analysis (GSEA) was performed to explore DEG-related signaling pathways. SPARCL1 expression in BC tissues and cell lines was verified by RT-qPCR. Further in vitro experiments were performed to investigate the biological functions of SPARCL1 in BC cells. Results We identified 332 liver metastasis-related DEGs from GSE124648 and 30 hub genes, including SPARCL1 , from the PPI network. GO and KEGG enrichment analyses of liver-metastasis-related DEGs revealed several enriched terms associated with the extracellular matrix and pathways in cancer. Clinicopathological correlation analysis of SPARCL1 revealed that its expression in BC was associated with age, TNM stage, estrogen receptor status, progesterone receptor status, histological type, molecular type, and living status of patients. GSEA results suggested that low SPARCL1 expression in BC was related to the cell cycle, DNA replication, oxidative phosphorylation, and homologous recombination. Lower expression levels of SPARCL1 were detected in BC tissues compared to adjacent tissues. The in vitro experiments showed that SPARCL1 knockdown significantly increased the proliferation and migration of BC cells, whereas the proliferation and migration were suppressed after elevating the expression of SPARCL1 . Conclusion We identified SPARCL1 as a tumor suppressor in BC, which shows potential as a target for BC and liver metastasis therapy and diagnosis.

SPARCL1 is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer

Abstract B20: Secreted Protein Acidic and Rich in Cysteines-Like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Immunological role and prognostic value of SPARCL1 in pan-cancer analysis

Secreted Protein Acidic And Rich In Cysteine, Like 1(Sparcl1), Inhibits Aggressiveness And Relates To Better Prognosis In Colorectal Cancers

The oncogenic functions of SPARCL1 in bladder cancer

SPARCL1 is a Novel Predictor of Tumor Recurrence and Survival in Hilar Cholangiocarcinoma

Down-Regulated Sparcl1 is Associated with Clinical Significance in Human Gastric Cancer

SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma

Integrated Analysis Reveals Down-Regulation of SPARCL1 is Correlated with Cervical Cancer Development and Progression

Identifying liver metastasis-related hub genes in breast cancer and characterizing SPARCL1 as a potential prognostic biomarker

SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.

SPARCL1, Shp2, MSH2, E-cadherin, P53, ADCY-2 and MAPK Are Prognosis-Related in Colorectal Cancer

SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation

Secreted Protein Acidic and Rich in Cysteine Expression in Human Colorectal Cancer Predicts Postoperative Prognosis

Sparcl1 Exhibits Different Expression Pattern Between Left- And Right-Sided Colon Cancer And It Was Down-Regulated Via Dna Methylation

Supplementary Figure 6 from <i>secreted Protein Acidic and Rich in Cysteines-like 1</i> Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Supplementary Figure 4 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

A Multi-Omics Analysis Reveals CLSPN is Associated with Prognosis, Immune Microenvironment and Drug Resistance in Cancers

SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response

Supplementary Figure 3 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Supplementary Figure 1 from Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers